An interventional study of Multidisciplinary intervention in Muscle Strengh, Frailty and Sarcopenia, sponsored by Consorci Sanitari del Maresme. Completed at 2 sites in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Consorci Sanitari del Maresme · Not applicable, Interventional, and Prevention
Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.
Among the 132 studies in Frailty with a site in Spain, this one is the 16th largest by enrollment of the 96 interventional ones that give a count, is one of 8 that started in 2021, is one of 93 with no phase, and was the 70th registered.
1,284 studies on the registry are indexed under Frailty; 451 are open to participants now.
Browse Frailty studies →46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:
Universidad de Granada · Sites in Spain
Ages 65+
University of Vigo · Sites in Spain
Ages 70+
Fundacion Miguel Servet · Sites in Spain
Ages 75+
Alberto Bermejo Franco · Sites in Spain
Ages 70+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 9 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 232 is above the median of 81 across 767 interventional studies indexed under Frailty.
Median enrollment 90 across the 96 interventional studies, 432 across the 36 observational. Of the 60 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 132 have an industry lead sponsor. The 10 most frequent:
Consorci Sanitari del Maresme is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
Consorci Sanitari del Maresme has 3 studies filed under Frailty — fewer than ten, so there is no comparison to draw.
11 of the studies in Frailty with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04926597Philipp SchuetzEffect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery | 2026-12 |
| NCT06556537Universidad de ZaragozaEffects of Physical Exercise on Frailty, Mental and Physical Health of Older Adults in Rural Areas. | 2026-12-20 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT07643064Alberto Bermejo FrancoMulticomponent Exercise and Comprehensive Geriatric Assessment Program (FRAIL+AP) for Frail Older Adults in Primary Care | 2026-12-31 |
| NCT07848802University of VigoPhysical Function and Fall Risk in Older Adults in the Lalín Frailty Prevention Program | 2027-01-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 132 studies in Frailty with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Frailty is a geriatric syndrome characterized by a decrease in the function of various organs and systems that leads to a greater risk of suffering from diseases or disabilities. Frailty is usually accompanied by weight loss, loss of strength, slowing of walking speed, fatigue and poor physical activity. Frail people have more difficulty in carrying out the usual activities of daily life and a greater risk of needing help to be able to do them.
The aim of this study is to evaluate the safety and effectiveness of an intervention based on the control of chronic diseases, a good use of medicines, diet, physical exercise and good social support, in the prevention . of frailty in old people who are at risk of frailty.
These criteria for participating in the study are why we invite you to participate. Your participation is voluntary. Your decision to participate or not in the study will not affect the medical care you may need. Before making a decision, read this information sheet carefully and ask the person who informs you the questions you want.
In the study there will be two groups, one will receive the study intervention and the other will not receive any special treatment (we call it the control group). The assignment of each individual to one group or the other will take place once you have decided to participate. This assignment will be made at random so that neither you nor your doctor can know "a priori" which group you will be in.
General objective:
To assess the effectiveness and safety of a multimodal and multidisciplinary intervention in the prevention of sarcopenia, frailty and functional decline in pre-frail community elders aged 70 years or older.
Specific objectives:
Evaluate the effect of the study intervention in the medium term (1 year) in terms of prevention or improvement of:
Secondary objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Usual clinical practice
* bimonthly personalized follow-up with the appropriate specialists (5 in a year) i * a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover: * General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition * Dietary and physical exercise recommendations in obese elderly * General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia * Physical exercise recommendations for the elderly at risk of falls. * Medication management and social resources for the elderly in Mataró.
Other: Multidisciplinary intervention
* bimonthly personalized follow-up with the appropriate specialists (5 in a year) i * a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover: * General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition * Dietary and physical exercise recommendations in obese elderly * General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia * Physical exercise recommendations for the elderly at risk of falls. * Medication management and social resources for the elderly in Mataró.
Muscle Mass
Bioimpedance
Time frame: baseline, 6 months and 12 months
Muscle strength and/or Muscle function
Isokinetic
Time frame: baseline, 6 months and 12 months
Sarcopenia
EWGSOP2 description
Time frame: baseline, 6 months and 12 months
Frailty
L Fried Criteria
Time frame: baseline, 6 months and 12 months
Functional Capacity 1
Barthel index
Time frame: baseline, 6 months and 12 months
Functional Capacity 2
Lawton index
Time frame: baseline, 6 months and 12 months
Functional Capacity 3
Timed up and go test
Time frame: baseline, 6 months and 12 months
Functional Capacity 4
SPPB
Time frame: baseline, 6 months and 12 months
Functional Capacity 5
Unipodal test
Time frame: baseline, 6 months and 12 months
Functional Capacity 6
Walking speed mesured by looking time to walk 4.6 meters
Time frame: baseline, 6 months and 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2021 to primary completion in Oct 2023, 23 months.
Of 513 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's 23 months is close to that.
Counting every sponsor, half of 517 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorci Sanitari del Maresme